Due to the lack of high-quality evidence and consensus on adjuvant treatment for locoregionally advanced penile cancer, we reviewed the outcomes of pN3 patients to determine the suitable adjuvant treatment options.
The concordance rate of bladder cancer (BCa) histological variants (HV) between transurethral resection of bladder tumor (TURBT) and radical cystectomy (RC) is sub-optimal and is unclear which factors may influence it.
White light (WL) is the traditional imaging modality for transurethral resection of bladder tumour (TURBT). IMAGE1S is a likely addition. We compare 18-mo recurrence rates following TURBT using IMAGE1S versus WL guidance.
Cabazitaxel was shown to improve overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) after abiraterone/enzalutamine and docetaxel failure, though benefit by the presence of DNA damage repair (DDR) defects is unknown.
It is estimated that clinical node-positive urothelial carcinoma of the bladder (cN+UCaB) affects approximately 5-10% of the patients that are diagnosed with muscle-invasive bladder cancer (MIBC).1 Its treatment presents a clinical challenge to the treating physician due to the ambiguity surrounding its regional versus metastatic classification. This is an important issue however as a significant […]
Urologic surgery has been at the forefront of robotic surgery development. Some may argue that robotic integration may soon take the place of the surgeon in the operating room. The authors of this article believe the contrary to be true. It is the onus of the surgeon, to continuously establish standards that are most efficient, […]
In prostate pre- and post-biopsy decision making, more precision is urgently needed. Whereas expert imaging and biomarker-based risk scores already enable the clinician in this respect, the dilemma remains for those patients that are diagnosed with apparent indolent cancer. Additional diagnostic tools that (de)select patients for active surveillance (AS) would provide a great benefit for […]
BACKGROUND: Decipher Biopsy is a commercially available gene expression classifier used in risk stratification of newly diagnosed prostate cancer (PCa). Currently, there are no prospective data evaluating its clinical utility. We seek to assess the clinical utility of Decipher Biopsy in localized PCa patients. METHODS: A multi-institutional study of 855 men who underwent Decipher Biopsy […]
The majority of urothelial carcinomas occur in the lower urinary tract, yet 5-10% originate in the upper urinary tract, including the renal calyces, renal pelvis, and ureters.1 Although upper and lower urinary tract urothelial carcinoma may share similar histology, the natural history differs, and upper tract disease often has a higher incidence of local invasion […]
A microscopic analysis of tissue is the gold standard for cancer detection. Hematoxylin-eosin (HE) for the reporting of prostate biopsy (PB) is conventionally based on fixation, processing, acquisition of glass slides, and analysis with an analog microscope by a local pathologist.
